The pharma industry’s reputation dropped slightly again among patient groups, largely due to drug pricing issues.

But international agreements are notoriously difficult to enforce, and pharma companies and patient advocates who were ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...

Pharma company Sudarshan Pharma Industries Limited (SPIL) has delivered a staggering 325 per cent return over the past five years, and is once again in investor spotlight after reporting a 45 per cent ...

The Trump administration’s threat of pharmaceutical tariffs could risk significant political backlash, as the drug industry ...

Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...

A Cambridge-based pharmaceutical company reported to the state that it is laying off close to a hundred employees.

European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...